Dr Dorit Samocha-Bonet
Conjoint Associate Professor

Dr Dorit Samocha-Bonet

Academic Record

2001 - 2006

PhD, Physiology and Pharmacology, Sackler School of Medicine, Tel-Aviv University, Israel.

1993 - 1996

MSc, Clinical Biochemistry, Sackler School of Medicine, Tel-Aviv University, Israel. With Honours.

1989 - 1992

BSc, Nutritional Sciences, Hebrew University, Faculty of Agricultural, Food and Environmental Quality Sciences, Israel. Cum Laude.


Other Qualifications

1993                                Dietitian (recognition by the Israeli Ministry of Health, Department of Medical Professions)

Medicine & Health
School of Clinical Medicine

Samocha-Bonet is Group leader, Clinical Insulin Resistance at the Healthy Ageing Theme at the Garvan Institute of Medical Research, and a Conjoint Senior Lecturer, School of Medical Sciences UNSW. Samocha-Bonet completed a BSc degree (Cum Laude) in Nutritional Sciences at the Hebrew University, Israel and joined the Nutrition & Dietetics Department at Tel Aviv Medical Centre as a clinical dietician where she worked for a decade (1993-2003). She completed MSc degree (with Honours) in Clinical Biochemistry (1996) and PhD in Physiology & Pharmacology (2006) at Tel Aviv University, Israel prior to relocating to Sydney. She joined the Garvan Institute of Medical Research in 2007 as a postdoctoral fellow. In 2013 she established the Clinical Insulin Resistance Group with a focus on exploring the metabolic factors underlying insulin resistance and insulin sensitivity in obesity and on developing approaches to promoting insulin sensitivity in obesity. She has been the Australian Diabetes Society (ADS) Skip Martin Early Career Fellow in 2011, and the recipient of the top ranked project grant from the Diabetes Australia Research Program in 2016.

Garvan Institute of Medical Research 384 Victoria Street Darlinghurst 2010
  • Journal articles | 2018
    Fazakerley DJ; Chaudhuri R; Yang P; Maghzal GJ; Thomas KC; Krycer JR; Humphrey SJ; Parker BL; Fisher-Wellman KH; Meoli CC; Hoffman NJ; Diskin C; Burchfield JG; Cowley MJ; Kaplan W; Modrusan Z; Kolumam G; Yang JYH; Chen DL; Samocha-Bonet D; Greenfield JR; Hoehn KL; Stocker R; James DE, 2018, 'Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance', eLife, vol. 7, http://dx.doi.org/10.7554/eLife.32111
    Journal articles | 2017
    Chen DLT; Brown R; Liess C; Poljak A; Xu A; Zhang J; Trenell M; Jenkins A; Chisholm D; Samocha-Bonet D; Macefield VG; Greenfield JR, 2017, 'Muscle sympathetic nerve activity is associated with liver insulin sensitivity in obese non-diabetic men', Frontiers in Physiology, vol. 8, http://dx.doi.org/10.3389/fphys.2017.00101
    Journal articles | 2016
    He J; Chen DL; Samocha-Bonet D; Gillinder KR; Barclay JL; Magor GW; Perkins AC; Greenfield JR; Yang G; Whitehead JP, 2016, 'Fibroblast growth factor-1 (FGF-1) promotes adipogenesis by downregulation of carboxypeptidase A4 (CPA4)–a negative regulator of adipogenesis implicated in the modulation of local and systemic insulin sensitivity', Growth Factors, vol. 34, pp. 210 - 216, http://dx.doi.org/10.1080/08977194.2017.1285764
    Journal articles | 2015
    Chen DL; Liess C; Poljak A; Xu A; Zhang J; Thoma C; Trenell M; Milner B; Jenkins AB; Chisholm DJ; Samocha-Bonet D; Greenfield JR, 2015, 'Phenotypic characterization of insulin-resistant and insulin-sensitive obesity', Journal of Clinical Endocrinology and Metabolism, vol. 100, pp. 4082 - 4091, http://dx.doi.org/10.1210/jc.2015-2712
    Journal articles | 2015
    Williams RS; Heilbronn LK; Chen DL; Coster A; Greenfield JR; Samocha-Bonet D, 2015, 'Dietary acid load, metabolic acidosis and insulin resistance - Lessons from cross-sectional and overfeeding studies in humans', Clinical Nutrition, vol. 35, pp. 1084 - 1090, http://dx.doi.org/10.1016/j.clnu.2015.08.002
  • Conference Abstracts | 2015
    Chen DLT; Chisholm D; Brown R; Macefield V; Samocha-Bonet D; Greenfield J, 2015, 'Liver insulin sensitivity is linked with resting sympathetic nervous activity in non-diabetic obese men', in DIABETOLOGIA, SPRINGER, SWEDEN, Stockholm, Vol. 58, pp. S121 - S121, presented at 51st Annual Meeting of the European-Association-for-the-Study-of-Diabetes (EASD), SWEDEN, Stockholm, 14 September 2015 - 18 September 2015, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359820900241&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Research at the Clinical Insulin Resistance Group at the Garvan is focused on uncovering the molecular pathways involved in the transition from health to insulin resistance and metabolic disease related to overweight and obesity in humans. In our clinical studies, we use gold-standard protocols to deeply phenotype individuals at risk of type 2 diabetes. Using gold-standard tools to characterise whole-body glucose regulation, abdominal fat distribution and liver fat, we find a wide range of phenotypic variation in obesity and prediabetes.

Current projects:

  1. A randomised clinical trial (https://clinicaltrials.gov/NCT03558867) to test the efficacy of an algorithm-based (personalised) diet in combination with metformin on glycaemia in individuals with prediabetes and type 2 diabetes (in collaboration with Prof Elinav and Prof Segal, The Weizmann Institute of Science).
  2. Reverse engineering insulin secretion in health and disease (in collaboration with leading obesity clinicians in hospitals across Sydney) - PhD project available in clinical study settings